Objective Identifying novel molecular drivers is crucial to improving therapeutic strategies for hepatocellular carcinoma (HCC). This study aimed to investigate the clinical significance and biological function of UDP-glucuronate decarboxylase 1 (UXS1) in HCC.
Methods UXS1 expression and its prognostic value were analyzed using the Gene Expression Profiling Interactive Analysis (GEPIA) database. In vitro, UXS1 was silenced in Huh-7 and HCCLM3 cell lines via siRNA. Malignant phenotypes were evaluated using CCK-8, Transwell, and wound healing assays. Transcriptome sequencing (RNA-seq) was performed to identify downstream mechanisms. Additionally, oxidative stress markers (catalase, superoxide dismutase, and glutathione) and key ferroptosis regulators (GPX4, SLC7A11) were assessed. Notably, rescue experiments using the ferroptosis inhibitor Ferrostatin-1 were conducted to validate the mechanism.
Results UXS1 mRNA expression was significantly upregulated in HCC tissues, and high expression correlated with poor overall and progression-free survival. Functionally, UXS1 knockdown significantly inhibited HCC cell proliferation, migration, and invasion. Transcriptome analysis of 425 differentially expressed genes (DEGs) highlighted the enrichment of reactive oxygen species (ROS) and ferroptosis-related pathways. Mechanistically, UXS1 silencing disrupted ROS homeostasis and downregulated the anti-ferroptotic proteins GPX4 and SLC7A11. Significantly, treatment with Ferrostatin-1 effectively reversed the tumor-suppressive effects of UXS1 knockdown.
Conclusion High expression of UXS1 serves as a prognostic biomarker for HCC. UXS1 knockdown suppresses HCC malignant progression, at least partially, by inducing ferroptosis via the SLC7A11/GPX4 axis. These findings suggest UXS1 is a potential therapeutic target and a novel ferroptosis checkpoint in HCC.
| [1] |
Bray F, Laversanne M, Sung Het al. . Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA A Cancer J Clin.. 2024, 74(3): 229-263
|
| [2] |
Yang X, Yang C, Zhang Set al. . Precision treatment in advanced hepatocellular carcinoma. Cancer Cell.. 2024, 42(2): 180-197.
|
| [3] |
Feng F, Zhao Y. Hepatocellular carcinoma: prevention, diagnosis, and treatment. Med Princ Pract.. 2024, 33(5): 414-423.
|
| [4] |
Pharkjaksu S, Cai H, Walter PJet al. . Elevated UDP-glucuronic acid levels mend drug resistance and stress responses via a protease and a transporter in Cryptococcus gattii. Proc Natl Acad Sci U S A.. 2025, 122(17. e2503960122
|
| [5] |
Brewer G. UXS1: a sweet spot for cell death. Nat Rev Cancer.. 2024, 241): 3.
|
| [6] |
Doshi MB, Lee N, Tseyang Tet al. . Disruption of sugar nucleotide clearance is a therapeutic vulnerability of cancer cells. Nature.. 2023, 6237987625-632.
|
| [7] |
Eames BF, Singer A, Smith GAet al. . UDP xylose synthase 1 is required for morphogenesis and histogenesis of the craniofacial skeleton. Dev Biol.. 2010, 341(2): 400-415.
|
| [8] |
Rustad CF, Backe PH, Jin Cet al. . A monoallelic UXS1 variant associated with short-limbed short stature. Mol Genet Genomic Med.. 2024, 12(6. e2472
|
| [9] |
Gnanapragasam A, Kirbizakis E, Li Aet al. . HiChIP-based epigenomic footprinting identifies a promoter variant of UXS1 that confers genetic susceptibility to gastroesophageal cancer. Cancer Res.. 2024, 8414): 2377-2389.
|
| [10] |
Gebru MT, Hoffman TE, Boudreau Aet al. . Loss of UXS1 selectively depletes pyrimidines and induces replication stress in KEAP1-mutant lung cancer. Cancer Res.. 2025, 85(23): 4806-4824.
|
| [11] |
Gan F, Zou A, Lv J. Expression and clinical significance of UXS1 in hepatocellular carcinoma [In Chinese]. Chinese Youjiang Medical Journal (Chinese).. 2025, 53(11): 989-995
|
| [12] |
Lv J, Gan FY, Li MHet al. . Silencing NCAPD3 inhibits tumor growth and metastasis in hepatocellular carcinoma by suppressing PI3K-AKT signalling pathway. Curr Med Sci.. 2025, 45(2): 253-263.
|
| [13] |
Juan CA, Pérez de la Lastra JM, Plou FJ, et al. The chemistry of reactive oxygen species (ROS) revisited: outlining their role in biological macromolecules (DNA, lipids and proteins) and induced pathologies. Int J Mol Sci. 2021;22(9):4642.
|
| [14] |
Liu J, Kang R, Tang D. Signaling pathways and defense mechanisms of ferroptosis. FEBS J.. 2022, 289(22): 7038-7050.
|
| [15] |
Xiao J, Luo C, Li Aet al. . Icariin inhibits chondrocyte ferroptosis and alleviates osteoarthritis by enhancing the SLC7A11/GPX4 signaling. Int Immunopharmacol.. 2024, 133. 112010
|
| [16] |
Li Q, Peng F, Yan Xet al. . Inhibition of SLC7A11-GPX4 signal pathway is involved in aconitine-induced ferroptosis in vivo and in vitro. J Ethnopharmacol.. 2023, 303. 116029
|
| [17] |
Xu X, Xu XD, Ma MQet al. . The mechanisms of ferroptosis and its role in atherosclerosis. Biomedecine Pharmacother.. 2024, 171. 116112
|
| [18] |
Gan B. Mitochondrial regulation of ferroptosis. J Cell Biol.. 2021, 220(9. e202105043
|
| [19] |
Gilles H, Garbutt T, Landrum J. Hepatocellular carcinoma. Crit Care Nurs Clin N Am.. 2022, 343): 289-301.
|
| [20] |
Wang Y, Deng B. Hepatocellular carcinoma: molecular mechanism, targeted therapy, and biomarkers. Cancer Metastasis Rev.. 2023, 42(3): 629-652.
|
| [21] |
Gao Q, Cheng B, Chen Cet al. . Dysregulated glucuronic acid metabolism exacerbates hepatocellular carcinoma progression and metastasis through the TGFβ signalling pathway. Clin Transl Med.. 2022, 12(8. e995
|
| [22] |
Sun B, Ding P, Song Yet al. . FDX1 downregulation activates mitophagy and the PI3K/AKT signaling pathway to promote hepatocellular carcinoma progression by inducing ROS production. Redox Biol.. 2024, 75. 103302
|
| [23] |
Xing L, Tang Y, Li Let al. . ROS in hepatocellular carcinoma: What we know. Arch Biochem Biophys.. 2023, 744. 109699
|
| [24] |
Li D, Zhang M, Liu Jet al. . Potential therapies for HCC involving targeting the ferroptosis pathway. Am J Cancer Res.. 2024, 144): 1446-1465.
|
| [25] |
Guo L, Hu C, Yao Met al. . Mechanism of sorafenib resistance associated with ferroptosis in HCC. Front Pharmacol.. 2023, 141207496.
|
| [26] |
Yang Y, Sun J, Cai J, et al. Chinese expert consensus on the whole-course management of hepatocellular carcinoma (2023 edition). Liver Cancer. 2025;14(3):311–333.
|
Funding
Guangxi Key Research and Development Program(no. AB22080064)
Guangxi Nanning Qingxiu District Key Research and Development Program of Science and Technology Plan(no. 2020050)
Guangxi Medical and Health Appropriate Technology Development, Promotion and Application Project(no. S2021097)
the Foundation of Scientiffc Research and Technology Development Project of Guangxi Province, China(GuiKeGong1355005-3-5)
RIGHTS & PERMISSIONS
The Author(s), under exclusive licence to the Huazhong University of Science and Technology
PDF
